- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Bydureon pen gets FDA approval
WILMINGTON, Del. — A new drug made by AstraZeneca is available in pharmacies following its regulatory approval in July, the company said Monday.
AstraZeneca announced the availability of the anti-platelet drug Brilinta (ticagrelor) for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.
The Food and Drug Administration approved Brilinta on July 20. AstraZeneca said the drug has been shown to reduce the rates of cardiovascular death, heart attacks and stroke, compared with other drugs on the market.